drugset / Trial / NCT02739815

Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section

NCT02739815

RandomizedParallel-groupTriple-blindPrevention

Summary

This study aims to define a safe prophylactic intravenous TXA dose with an advantage over others in reducing total blood loss volume at secondary uncomplicated LSCS.

Timeline

Start
2016-04
Primary completion
2016-06
Completion
2016-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 15 mg/kg Intravenous
Comparator Tranexamic Acid Small molecule 20 mg/kg Intravenous
Comparator Tranexamic Acid Small molecule 25 mg/kg Intravenous

Indications

No indication recorded.